BRIEF—Arctoris and Molecule pair up to 'tackle innovation crisis'

UK-based Arctoris, which calls itself the developer of the world’s first fully automated drug discovery platform, has said that its new collaboration will tackle the industry’s ‘innovation crisis’.

Arctoris will work with Molecule, a Swiss company with a platform to accelerate innovation in pharma, with the aim of making drug discovery and development faster, cheaper, less risk-prone, and more viable at all levels.

Martin-Immanuel Bittner, co-founder and chief executive of Arctoris, said: “Drug discovery researchers worldwide face enormous challenges posed by a widespread lack of reproducibility and the limited availability of standardized, structured, high quality data.

“By partnering with Molecule, we intend to make drug discovery and development more democratic, collaborative, and efficient in the interest of bringing higher-quality therapeutics to patients faster through the combination of robotics, AI and a distributed research platform.”